Moderna and Merck claim a hard-won melanoma vaccine breakthrough
TL;DR
Topline results from a large trial show Moderna and Merck’s cancer vaccine, intismeran autogene, reduced recurrence or spread of surgically removed melanoma, signaling a milestone after years of doubt and pandemic-related hurdles—though some scientists urge waiting for fuller data and longer follow-up before declaring a definitive breakthrough.
- Inside Moderna and Merck’s cancer vaccine triumph STAT
- What it was like to go through a trial that could revolutionize cancer treatment The Washington Post
- Hype for Moderna’s Cancer Vaccine Is Running Ahead of the Math WSJ
- A New mRNA Vaccine Could Prevent Skin Cancer From Returning The New York Times
- Wisconsin doctor responds to ‘breakthrough trial’ of new cancer vaccine WPR
Want the full story? Read the original reporting
Read on STAT